Registered title, quoted from ClinicalTrials.gov
Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Union Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07899047, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically and/or cytologically confirmed HER2-negative recurrent or metastatic breast cancer (HER2-negative subtype includes HR-positive HER2-negative and triple-negative breast cancer);
Inclusion criterion 2
No restrictions on prior lines or regimens for recurrent/metastatic disease (e.g., endocrine therapy, CDK4/6 inhibitors, ADC agents, chemotherapy, immunotherapy, etc.). For patients previously exposed to taxane-based therapy in the neoadjuvant, adjuvant, or metastatic-disease setting, recurrence or disease progression must have occurred > 12 months after the last taxane administration;
Inclusion criterion 3
History of malignancies other than breast cancer within 5 years prior to the first study drug dose, except for cured malignancies such as in-situ carcinoma and basal-cell carcinoma;
Exclusion criterion 4
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
Inclusion criterion 4
At least one measurable lesion per RECIST version 1.1. Patients with bone-only metastases without measurable lesions are eligible;
Inclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07899047, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Aged ≥ 18 years;
- Histologically and/or cytologically confirmed HER2-negative recurrent or metastatic breast cancer (HER2-negative subtype includes HR-positive HER2-negative and triple-negative breast cancer);
- No restrictions on prior lines or regimens for recurrent/metastatic disease (e.g., endocrine therapy, CDK4/6 inhibitors, ADC agents, chemotherapy, immunotherapy, etc.). For patients previously exposed to taxane-based therapy in the neoadjuvant, adjuvant, or metastatic-disease setting, recurrence or disease progression must have occurred > 12 months after the last taxane administration;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- At least one measurable lesion per RECIST version 1.1. Patients with bone-only metastases without measurable lesions are eligible;
- Planned to receive monotherapy or combination regimens containing either Paclitaxel for Injection (Albumin Bound) (Ⅱ) or paclitaxel for injection (albumin-bound). Combination partners include, but are not limited to, PD-1 inhibitors, capecitabine, gemcitabine, cisplatin, and carboplatin;
- Fully informed and voluntarily provides written informed consent for study participation.
Exclusion Criteria:
- Known hypersensitivity or intolerance to study drugs or their excipients;
- Concurrent participation in other interventional clinical studies;
- Uncontrolled third-space effusions (e.g., massive pleural, peritoneal, pericardial effusion) that cannot be stabilized (i.e., no further intervention required after drainage). Patients with small, asymptomatic pleural or peritoneal effusions identified by imaging are permitted;
- History of malignancies other than breast cancer within 5 years prior to the first study drug dose, except for cured malignancies such as in-situ carcinoma and basal-cell carcinoma;
- Active brain metastases (including symptomatic brain metastases or leptomeningeal metastases).
Quoted from ClinicalTrials.gov, NCT07899047, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07899047, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.